Sep 14, 2026 7:45 am EDT TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
Sep 8, 2026 7:45 am EDT TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Aug 14, 2026 7:45 am EDT TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Jul 22, 2026 7:40 am EDT TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Jun 15, 2026 7:45 am EDT TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers
May 15, 2026 5:00 pm EDT TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 12, 2026 7:30 am EDT TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
Apr 22, 2026 7:30 am EDT TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Apr 7, 2026 7:45 am EDT TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Apr 1, 2026 7:45 am EDT TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update